RayKnowChina Research Map
Shortlist

Not yet recruitingLymphomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Sun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07753642, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically confirmed nodal T-follicular helper (TFH) cell lymphoma according to the 2022 WHO classification.

    Inclusion criterion 1

  3. Patients who have received systemic corticosteroids or other immunosuppressive therapy within 14 days before the start of study treatment.

    Exclusion criterion 11

  4. An ECOG performance status score of 0-1.

    Inclusion criterion 6

  5. At least one measurable or evaluable lesion according to the Lugano 2014 criteria.

    Inclusion criterion 4

  6. Patients with a history of other malignancies within the past 5 years or concurrent malignancies, except for basal cell carcinoma of the skin.

    Exclusion criterion 3

    Patients with active infections, including tuberculosis, HIV infection, active hepatitis B, or active hepatitis C.

    Exclusion criterion 5

  7. Pregnant or breastfeeding women and participants of childbearing potential unwilling to use effective contraception.

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07753642, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Key inclusion Criteria:

  • Histologically confirmed nodal T-follicular helper (TFH) cell lymphoma according to the 2022 WHO classification.
  • Previously untreated with systemic anti-lymphoma therapy.
  • Age ≥18 and <75 years.
  • At least one measurable or evaluable lesion according to the Lugano 2014 criteria.
  • An expected survival time of more than 12 weeks.
  • An ECOG performance status score of 0-1.
  • Adequate organ and bone marrow function.
  • Provision of written informed consent and willingness to comply with all study procedures.

Key exclusion Criteria:

  • Hemophagocytic syndrome.
  • Central nervous system or meningeal involvement by lymphoma.
  • Patients with a history of other malignancies within the past 5 years or concurrent malignancies, except for basal cell carcinoma of the skin.
  • Patients receiving potent CYP3A inducers or inhibitors, vitamin K antagonists, antiplatelet agents, or anticoagulants.
  • Patients with active infections, including tuberculosis, HIV infection, active hepatitis B, or active hepatitis C.
  • Patients with severe or uncontrolled cardiovascular disease.
  • Patients with a history of interstitial lung disease, except for asymptomatic radiation-induced interstitial lung disease.
  • Patients with gastrointestinal conditions that may interfere with oral administration or drug absorption.
  • Patients with known hypersensitivity to golidocitinib or its excipients.
  • Pregnant or breastfeeding women and participants of childbearing potential unwilling to use effective contraception.
  • Patients who have received systemic corticosteroids or other immunosuppressive therapy within 14 days before the start of study treatment.
  • Patients considered unsuitable for participation by the investigator.

Quoted from ClinicalTrials.gov, NCT07753642, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07753642, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07753642